PAC Cardio-1 B4
Contenido
REFERENCIAS
  1. Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol 1994;23:1273-1277.

  2. Ockene IS, Ockene JK. Barriers to lifestyle change, and the need to develop an integrated approach to prevention. Cardiol Clin 1996;14:159-169.

  3. López R, Villa Soto JC, Esquivel I. La transición epidemiológica. Los nuevos perfiles de México. Ciencia Med 1994;1:11-23.

  4. Subsecretaría de Planeación. Dirección General de Estadística e Informática Mortalidad 1995. México, D.F.

  5. Recomendaciones de la Segunda Reunión de Expertos en Dislipidemias organizada por la Asociación Mexicana para la Prevención de la Aterosclerosis y sus Complicaciones, A.C. Lineamientos sobre la detección, el manejo diagnóstico y el tratamiento dietario y farmacológico de la hipercolesterolemia y la hipertrigliceridemia. Rev Mex Cardiol 1996;7:7-24.

  6. Blackburn H. The concept of risk. En: Pearson TA, Criqui MH, Luepker RV et al. ed. Primer in preventive cardiology. Dallas: American Heart Association, 1994:25.

  7. Miller M, Vogel RA. The practice of coronary disease prevention. Baltimore, Md.: Williams & Wilkins, 1996:175-207.

  8. Haynes SG, Eaker DE, Feinleib M. Spouse behavior and coronary heart disease in men: Prospective results from the Framingham Heart Study. Am J Epidemiol 1983;118:1-22.

  9. Haynes SG, Levine S, Scotch N et al. The relation of psychosocial factors to coronary heart disease in the Framingham Study. Am J Epidemiol 1978;107:362-383.

  10. Stamler J, Dyer AR, Shekelle RB et al. Relationship of baseline major risk factors to coronary and all causes mortality, and to longevity: Findings from long-term followup of Chicago cohorts. Cardiology 1993;82:191-222.

  11. La Rosa JC. Cholesterol and cardiovascular disease: How strong is the evidence? Clin Cardiol 1992;15 (supl. III):III-2 - III-7.

  12. Keys A, Aravanis C, van Buchem FSP et al. The diet and all-causes death rate in the Seven Countries Study. Lancet 1981;2:1127-1135.

  13. Castelli WP, Garrison KJ, Wilson PW et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-2838.

  14. Martin MJ, Hulley SB, Browner WS et al. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361 662 men. Lancet 1986;2:933-936.

  15. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989;79:8-15.

  16. Green MS, Heiss G, Rifkind BM et col. The ratio of plasma high density lipoprotein cholesterol to total and low density lipoprotein cholesterol: age-related changes and race and sex differences in selected North American populations; the Lipid Research Clinics Program Prevalence Study. Circulation 1985;72:93-104.
  17. Grundy SM. Atlas de las alteraciones de los lípidos. Vol. 1. Hong Kong: Gower Medical Publishing y Merck & Co., 1990:36.

  18. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. JAMA 1987;257:2176-2180.

  19. Marmot MG, Syme SL, Kagan A et al. Epidemiologic studies of CHD and stroke in Japanese men living in Japan, Hawaii and California. Prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol 1975;102:514-521.

  20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.

  21. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Arch Intern Med 1992;152:28-34.

  22. Assman G, Schulte H. Triglycerides and atherosclerosis: Results from the Prospective Cardiovascular Münster study. Atherosc Rev 1991;22:51-57.

  23. Criqui MH, Heiss G, Cohn R et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220-1225.

  24. Cambien F, Jacqueson A, Richard JL et al. Is the level of serum triglyceride a significant predictor of coronary death in “normocholesterolemic” subjects? The Paris prospective study. Am J Epidemiol 1986;124:624-632.

  25. Castelli WP. The triglycerides issue: A view from Framingham. Am Heart J 1986;112:432-437.

  26. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.

  27. Thompson GR. A handbook of hyperlipidaemia. Londres: Current Science & Merck, 1989:6-7.

  28. Mahley RW, Innerarity TL, Rall SC et al. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984;25:1277-1294.

  29. Magos López C. Lipoproteínas y apoproteínas. En: Zorrilla Hernández E, ed. Lípidos séricos en la clínica. 2a ed. México: Interamericana-McGraw.Hill, 1989:30-45.

  30. Hunninghake DB. Clinical perspectives in blood lipids. 2. Lipoprotein metabolism. Londres: Current Medical Literature,1988:42.

  31. Ahumada Ayala M. Transporte de los lípidos séricos: metabolismo de las lipoproteínas. En: Zorrilla Hernández E. Op. cit.

  32. Gotto AM, Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins. En: Segrest JP, Albers JJ, ed. Methods in enzymology. Londres: Academic Press, 1986;3-41.

  33. McLean LR, Demer RA, Socorro I et al. Mechanism of action of lipoprotein lipase. En Segrest JP, Albers JJ. Op.cit.

  34. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.

  35. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low-density lipoprotein in normal humans. J Lipid Res 1982;23:97-104.

  36. Castelli WP, Garrison RJ, Wilso PWF et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Heart Study. JAMA 1986; 256:2835-2838.

  37. Austin MA, King MC, Vranizan KM et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.

  38. Campos H, Blijlevens E, McNamara JR. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb 1992;12:1410-1419.

  39. Swinkels DW, Demacker PNM, Hendrick JCM et al. Low density lipoprotein subfractions and relationship of the other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis 1989;9:604-613.

  40. Hokanson JE, Krauss RM, Albers JJ et al. LDL physical and chemical properties in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1995;15:452-459.

  41. Brewer HB, Santamarina-Fojo S, Hoeg JM. Molecular biology of the lipoprotein and apolipoproteins and their role in atherosclerosis. En: Roberts R, ed. Molecular basis of cardiology. Boston: Blackwell Scientific Publications, 1993: 422

  42. Tall AR. Plasma high-density lipoprotein: Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379-384.

  43. Hamilton RL Williams MC, Fielding CJ et al. Discoidal bilayer structure of nascent high-density lipoproteins from perfused rat liver. J Clin Invest 1976;58:667-680.

  44. Huang Y, von Eckardstein A, Assman G. Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. Arterioscler Thromb 1993;13:445-458.

  45. Brown MS, Goldstein JL. The LDL receptor concept: Clinical and therapeutic implications. Atherosc Rev 1988;18:85-94.

  46. Libby P. Atheroma: more than much. Lancet 1996;348(supl I):s4-s6.

  47. Bloch K. Biological synthesis of cholesterol. Science 1965;150:19-28.

  48. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - An integrated approach to mechanisms and disorders. N Engl J Med 1977;276:34-44;94-103;148-156;215:224;273-281.

  49. Ahumada Ayala M. Dislipoproteinemia. Metabolismo de las lipoproteínas. En: Cueto García L, ed. Prevención de la aterosclerosis en México. México, D.F.: AMPAC, 1989:62.

  50. Goldstein JL, Schrott HG, Hazzard WR et al.Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52: 1544-1568.

  51. Sprecher DL, Hoeg JM, Schaefer EJ et al. The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolaemia. Metabolism 1985;34:294-299.
  52. Gagné C, Moorjani S, Brun D et al. Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischemic heart disease in men and women. Atherosclerosis 1979; 34:13-24.

  53. Thompson GR. Op. cit.:143-156.

  54. Miller M, Vogel RA. Op. cit.:29-34

  55. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.

  56. Illinworth R. Clinical perspectives on blood lipids. Londres: Current Medical Literature, 1989.

  57. Study Group. Policy statement of the European Atherosclerosis Society of prevention of coronary heart disease. Eur Heart J 1987;8:77-88.

  58. Guadalajara Boo F, Meaney E. Remodelación ventricular, cardiorreparación y cardioprotección. México, D.F.: Intersistemas SA de CV, 1997:36.

  59. Brownsell VL, Griffith CJ, Jones E. La ciencia aplicada al estudio de los alimentos. México, D.F.: Editorial Diana, 1993:59-80.

  60. Luna Castaños G, Cueto García L, Viniegra Osorio A. Nutrición y aterosclerosis. En: Cueto García L. Op. cit.:151-166.

  61. Thompson GR. Lipids, fish and coronary heart disease. Curr Opin Cardiol 1986; 1:827-831.

  62. Grundy SM, Bilheimer D, Blackburn H et al. Rationale of the diet-heart statement of the American Heart Association. Report of Nutrition Committee. Circulation 1982;65: 839A-854A.

  63. Gaziano JM, Buring JE, Breslow JL et al. Moderate alcohol intake, increase level of high-density lipoprotein and its subfractions, and decrease risk of myocardial infarction. N Engl J Med 1993;329:1829-1834.

  64. Renaud S, de Lorgeril M.Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet 1992; 339:1523-1526.

  65. de Lorgeril M, Salen P, Martin J-L et al. Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. J Am Coll Cardiol 1996;28:1103-1108.

  66. Eshleman R, Winston M, ed. American Heart Association cookbook. 5a ed. Dallas, Tx.: American Heart Association, 1991:10-12.

  67. Alberts AW. HMG-CoA reductase inhibitors- The development. Ateroscl Rev 1988;18:123-131.

  68. The Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: A multicenter study. JAMA 1986;256:2859-2834.

  69. Bradford RH, Shear CL, Chremos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.

  70. Walker JF. HMG CoA reductase inhibitors. Current clinical experience. Drugs 1988;36 (supl3):83-86.

  71. Sheperd J, Cobre SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.

  72. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;334:1384-1389.

  73. Blakenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994;14:177-192.

  74. Illingworth DR. Drug therapy of hypercholesterolemia. Clin Chem 1988;34:123B-132B.

  75. Glueck CJ, Ford S, Scheel D et al. Colestipol and cholestiramine resin. Comparative effects in familial type II hyperlipoproteinemia. JAMA 1972;222:678-681.

  76. Lipid Research Clinics program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:351-364.

  77. Brensike JF, Levy RI, Kelsey SF et al. Effects of therapy with cholestiramine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;289: 220-223.

  78. Recommendations of the European Atherosclerotic Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab CardiovasDis 1992;2:113-156.

  79. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.

  80. Grundy SM, Mock HYI, Zeck L et al. The influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981:26:1464-1475.

  81. Illingworth DR. Lipid lowering drugs: an overview of indications and optimum therapeutic use. Drugs 1987;33:259-279.

  82. Taskinen M-R, Nikkila EA. Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia. Atherosclerosis 1988;69;249-255.

  83. Kesaniemi YA, Grundy SM. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984;251:2241-2246.

  84. Report from the Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-1118.

  85. Ericsson C-G, Hamsten A, Nilsson J et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.

  86. Berry CL, Sosa-Melgarejo JA. Structure and function of the arterial system in hypertension. En: Safar ME, O´Rourke MF, ed. The arterial system in hypertension. Dordrecht: Kluwer Academic Publishers, 1993:55-72.

  87. Meaney E, Moguel R. Epidemiología de la hipertensión arterial sistémica. En: Meaney E, ed. Hipertensión arterial sistémica. Mecanismos, diagnóstico y tratamiento. México, D.F.: MIND, 1991:54.

  88. Meaney E. La hipertensión arterial como factor de riesgo cardiovascular. En: Cueto Cardía L, ed. Prevención de la aterosclerosis en México. México D.F.: AMPAC, 1989:l04-107.

  89. Pooling Project Research Group. Relationship of blod pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chron Dis 1978;31:201-305.

  90. The Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-182.

  91. Kannel W. B. Hypertension and other risk factors in coronary heart disease. Am Heart J 1987;114:918-925.

  92. Black HR. The coronary artery disease paradox. The role of hyperinsulinemia and insulin resistance and implications for therapy. J Cardiovasc Pharmacol 1990;15 (supl 5):S26-S38.

  93. Oparil S. Antihypertensive therapy and atherosclerosis in coronary heart disease. Cardiovasc Risk Factors 1996;6: 222-232.

  94. SHEP Cooperative Research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991;265:3255-3264.

  95. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338: 1281-1285.

  96. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-412.

  97. Elmer PJ. Obesity and cardiovascular disease: practical approaches for weight loss in clinical practice. En: Pearson TA, Criqui MH, Luepker R et al, ed. Primer in preventive cardiology. Dallas, Tx: American Heart Association, 1994: 189-204.

  98. Neaton JD, Grimm Jr RH, Prineas RJ et al. Treatment of mild hypertension study. Final results. JAMA 1993;270:713-724,

  99. Encuesta Nacional de Enfermedades Crónicas. México, D.F.: Dirección General de Epidemiología, Secretaría de Salud, 1994.

  100. Guía para la prevención y control de la hipertensión arterial esencial en la atención primaria a la salud. México, D.F.: Sistema Nacional de Salud, Medicina Preventiva, 1994:1.

  101. US Department of Health and Human Services, Office of the Surgeon General. The health benefits of smoking cessation. A Report of the Surgeon General, 1990. DHHS publication No. (CDC) 90-8416. Rockville, Md. US Department of Health and Human Services, Public Health Service. 1990.

  102. Wilhelmsen L. Coronary heart disease: Epidemiology of smoking and intervention studies of smoking. Am Heart J 1998;115:242-249.

  103. Meaney E, Rivera JM. La lucha contra el tabaquismo en la prevención de la aterosclerosis en México. En: Cueto García L.Op cit:75.

  104. Organización Panamericana de Salud. Tabaco o salud: Situación en México. Washington, DC. OPS, 1992:261.

  105. Tapia Conyer R. Prevalencia del tabaquismo en México en las encuestas nacionales de salud. En: Simposio Internacional sobre Tabaquismo. Papel del profesional de la salud en la ayuda al paciente fumador. México, D.F. Centro de Comunicación Médica Ciba-Geigy, 1992:17-26.

  106. Cook DG, Shaper AG, Focock SJ et al. Giving up smoking and the risk of heart attacks. Lancet 1986;2:1376-1379.

  107. Sleight P. Risk factors and coronary heart disease. Postgrad Cardiovasc Sem 1988;1:3-14.

  108. Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984;26:373-412.

  109. García MJ, McNamara PM, Gordon T et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-111.

  110. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987;28:613-628.

  111. Feskens EJM, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study. Arteroscler Thromb 1994;14:1641-1647.

  112. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 1996;329:977-986.

  113. Larsson B, Svardosoud K, Wellin L et al. Abdominal tissue distribution, obesity, and risk of cardiovascular disease and death: 13 years follow up of participants in the study of men born in 1913. Br Med J 1988;288:1401-1404.

  114. Harris TH, Cook EF, Garrison R et al. Body mass index and mortality among nonsmoking older persons. The Framingham heart study. JAMA 1988;259:1520-15224.

  115. Hubert HB, Feinleib M, McNamara PM et al. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Study. Circulation 1983;67:968-977.

  116. Oberman A. Excercise and coronary prevention of coronary artery disease. Am J Cardiol 1985;55:10D-20D.

  117. Meaney E, Rodríguez Saldaña J. Factores secundarios en el desarrollo de la aterosclerosis: Sedentarismo, estrés y obesidad. En Cueto García L. Op cit:111-130.

  118. Paffenbarger RS, Wing AL, Hyde RT. Physical activity as an index of heart attack risk in college alumni. Am J Epidemiol 1968;88:25-30

  119. Vandenbroucke JP. Postmenopausal oestrogen and cardioprotection. Lancet 1991; 337:833-834.

  120. Danlen GH, Guyton JR, Attar M et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-765.

  121. Rader DJ, Brewer HB Jr. Lipoprotein(a). Clinical approach to a unique atherogenic lipoprotein. JAMA 1992;267:1109-1112.

  122. Wade DP. Lipoprotein(a). Curr Opin Lipidol 1993;4:244-249.

  123. Ridker PM, Hennekens CH. Hemostatic risk factors for coronary heart disease. Circulation 1991;83:1098-1100.

  124. Kanell WB, Wolf PA, Castelli WP et al. Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 1987;258: 1183-1186.

  125. Genest JJ Jr, McNamara JR, Salem DN et al. Plama homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990;16:1114-1119.

  126. Epstein SE, Speir E, Zhou YF. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet 1996;348 (supl 1):s13-s17.

  127. Gloria F, Meaney E, Valero G et al. La relación entre Chlamydia pneumoniae y las lesiones aterosclerosas coronarias. Arch Inst Cardiol Mex 1997;67:17-23.

  128. Gloria F, Meaney E, Rivera J et al. Complejo hostil e infarto del miocardio. Arch Inst Cardiol Mex 1996;66:138-142.

  129. Stehbens WE. The lipid hypothesis and the role of hemodynamics in atherogenesis. Prog. Cardiovasc Dis 1990;33:119-136.

  130. St Clair RW. Pathogenesis of atherosclerosis. Cardiol Rev 1997;5:14-24.

  131. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362: 801-809.

  132. Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arteroscler Thromb 1994;14:840-856.

  133. Stary HC, Chandler AB, Dinsmore RE et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Throm 1995;15:1512-1531.

  134. Gimbrone MA. Endotelial dysfunction and vascular disease. En: Dal Palú C, Ross R, ed. Hypertension and atherosclerosis. Amsterdam: Excerpta Medica, 1989:50-53.

  135. Lüscher TF, Vanhoutte PM. The endothelium: Modulator of cardiovascular function. Boca Ratón: CRC Press Inc. 1990:1-228.

  136. Steinberg D. Modified forms of low-density lipoprotein and atherosclerosis. J Int Med 1993;233:227-232.

  137. Faruqi RM, DiCorleto PE. Mechanisms of monocyte recruitment and accumulation. Br Heart J 1993;69:S19-S29.

  138. Woolf N. Morphological changes in atherosclerosis and the effect of hyperlipidemia on the artery wall. Ateroscl Rev 1988;18:25-48.

  139. Jang Y, Lincoff M, Plow EF et al. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994;24:1591-1601.

  140. Libby P, Ross R. Citokines and growth regulatory molecules. En Fuster V, Ross R, Topol E (eds). Atherosclerosis and coronary artery disease. Nueva York: Lippincott-Raven, 1996:585-594.

  141. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of artherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992;90:1138-1144.

  142. Malek AM, Izumo S. Molecular aspects of signal transduction of shear stress in the endothelial cell. J Hypertension 1994;12:989-999.

  143. Adams DH, Shaw S. Leukocyte-endothelial interactions and regulation of leukocyte migration. Lancet 1994;343:831-836.

  144. Inoue I, Inaba T, Motoyoshi K et al. Macrophages colony stimulating factor prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 1992;93:245-254.

  145. Rhodin JAG. Architecture of the vessel wall. En: Bohr DF, Somlyo AP, Sparks HV Jr, ed. Handobook of Physiology. Section 2. The cardiovascular system. Bethesda, Md: American Physiological Society, 1980:1=29

  146. Mirsky I. Elastic properties of the myocardium: a quantitative approach with physiological and clinical applications. En: Bohr DF, Somlyo AP, Sparks HV Jr, ed. Handbook of Physiology. Section 1. The cardiovascular system. Bethesda, Md.: American Physiological Society, 1980:497-527.

  147. Nekrasov B. Hidráulica. 3a. edición. Moscú: Editorial MIR, 1988:13-20.

  148. Fuster V, Badimon L, Badimon JJ et al. The pathogenesis of coronary artery disease and the acutte coronary syndromes. N Engl J Med. 1992;326:310-318.

  149. Davies MJ, Richardson PD, Woolf N et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipids, macrophages, and smooth muscle content. Br Heart J 1993;69:377-381.

  150. Fernández-Ortíz A, Badimon JJ, Falk E et al. Characterization of the relative thrombogenicity of atheosclerotic plaque components: Implications for consequence of plaque rupture. J Am Coll Cardiol 1994;23:1562-1569.

  151. Walpola PL, Gotlieb AI, Cibulsky MI et al. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shera stress. Aterioscler Thromb 1995;15:2-10.

  152. Nquyen ND, Haque AK. Effect of hemodynamic factors in atherosclerosis abdominal aorta. Atherosclerosis 1990:84:33-39.

  153. Mustard JF, Packham MA. Factors influencing platelet function: adhesion release and aggregation. Pharmacol Rev 1970;22:97-102.

  154. Libby P, Warner SJ, Saloman RN et al. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med 1988;318: 1493-1498.

  155. Blakenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994;14:177-192.
Contenido
Copyright © 2005 Dr. Scope. Derechos Reservados.
Diseño y Programación: Educación Médica Contínua